The Latest Breaking News from Novo Nordisk

Liraglutide appeared to reduce brain shrinkage in people with early-stage Alzheimer’s, a small UK study reports

A rise in counterfeit versions of sought-after weight loss drug has led to a series of hospitalisations.

Small pharmacies find difficulty in prescribing the drug due to Big Pharma restrictions on the industry. ‌

With strong first-quarter results and promising growth in its diabetes and obesity treatments, all eyes are on Novo Nordisk’s (NVO) to see if the pharmaceutical giant can maintain its momentum. Will the upcoming second-quarter earnings report reflect its market potential? Learn more to find out….

As nearly $1 billion of venture capital dollars have been injected into weight-loss startups since 2023, companies are making unproven claims to attract customers. It’s a new twist on a story as old as the diet industry.

Shares in Novo Nordisk were down 1.1% after the study

Patients taking Eli Lilly's new drug Mounjaro achieved significantly greater weight loss than those on Novo Nordisk's Ozempic, a head-to-head study published Monday showed.

Remarks came after the president and Senator Bernie Sanders blasted the pharmaceutical giant for its ‘unconscionably high prices’

People with diabetes on semaglutide, found in Wegovy and Ozempic, four times more likely to be diagnosed with disease of optic nerve